Advertisement

Topics

Bristol-Myers Squibb and Gritstone Oncology Partner to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

16:14 EDT 19 Jul 2018 | Speciality Pharma Journal

EMERYVILLE, Calif. & NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001, which comprises sequential delivery of neoantigens to patients within an adenovirus-based vector (prime) and a self-replicating RNA-based vector (boost), in combination …

Original Article: Bristol-Myers Squibb and Gritstone Oncology Partner to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb and Gritstone Oncology Partner to Evaluate Novel Immunotherapy Approach in Advanced Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...